A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Trial Details

NCT ID

NCT07291076

Phase

PHASE1 / PHASE2

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

• Pumitamig
• Ipilimumab
• Atezolizumab
• Bevacizumab

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368
• Chicago, Illinois, United States|41.85003,-87.65005
• Hackensack, New Jersey, United States|40.88593,-74.04347
• Mineola, New York, United States|40.74927,-73.64068
• Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

• Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).
• Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Participants must have no prior systemic therapy for advanced/ unresectable HCC.
• Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.